Prognostic criteria for the development of severe clinical forms of COVID-19 in medical organization workers
AbstractEmployees of medical organizations are one of the risk groups for infection with a new coronavirus infection (COVID-19), including with the development of severe clinical forms.
The aim of the study was to analyze the clinical manifestations of a new coronavirus infection in medical workers with the determination of laboratory markers for the development of severe COVID-19.
Material and methods. The study included 186 medical workers who had COVID-19 in 2020. In 67 people (observation group), the disease occurred in the form of pneumonia, in 119 people (comparison group) – acute respiratory infection caused by SARS-CoV-2. In the acute period of the disease, a laboratory examination was carried out: a general clinical blood test, CD-typing of lymphocyte subpopulations, assessment of biochemical parameters, determination of parameters of the hemostasis system and cytokine levels.
Using the binary logistic regression method, we have built multifactor models. To determine the threshold values of the indicators, we used ROC analysis. Statistical processing of materials was carried out using Microsoft Office 2016 and IBM SPSS Statistics (version 26). The differences were considered statistically significant at p<0.05.
Results and discussion. The most frequent clinical manifestations of COVID-19 were: weakness, fever, myalgia, arthralgia, difficulty in nasal breathing, serous-mucous discharge from the nose, sore throat, cough, feeling of “tightness” in the chest, shortness of breath, headache, pain in the eyeballs, dizziness, anosmia, ageusia and dyspeptic manifestations in the form of diarrhea, nausea or vomiting.
Markers associated with the development of severe pneumonia associated with COVID-19 have been identified. Threshold values of laboratory parameters for predicting the severe course of COVID-19 were determined: the number of platelets (less than 239×109/l), lymphocytes (less than 1.955×109/l), cytotoxic T-lymphocytes (less than 0.455×109/l), T-helper cells (less than 0.855×109/l), NK-cells (less than 0.205×109/l), ESR (more than 11.5 mm/h), LDH (more than 196 units/l), total protein (less than 71.55 g/l), D-dimer (more than 0.325 mcg/ml), CRP (more than 4.17 mg/l), IL-6 (more than 3.63 pg/l).
Conclusion. The data obtained make it possible to predict the possibility of developing a severe variant of the COVID-19 course.
Keywords:coronavirus infection; COVID-19; medical workers; clinical manifestations; laboratory markers; threshold values; prognostic criteria
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
Contribution. Concept and design of the study – Platonova T.A., Semenenko T.A., Golubkova A.A.; collection and processing of the material – Platonova T.A., Sklyar M.S., Karbovnichaya E.A., Sisin E.I.; statistical processing, text writing – Platonova T.A., Karbovnichaya E.A., Smirnova S.S.; editing, approval of the final version of the article – Semenenko T.A., Golubkova A.A.
For citation: Platonova T.A., Semenenko T.A., Golubkova A.A., Sisin E.I., Sklyar M.S., Karbovnichaya E.A., Smirnova S.S. Prognostic criteria for the development of severe clinical forms of COVID-19 in medical organization workers. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2022; 11 (4): 19–29. DOI: https://doi.org/10.33029/2305-3496-2022-11-4-19-29
References
1. Calò F., Russo A., Camaioni C., De Pascalis S., Coppola N. Burden, risk assessment, surveillance and management of SARS-CoV-2 infection in health workers: a scoping review. Infect Dis Poverty. 2020; 9 (1): 139. DOI: https://doi.org/10.1186/s40249-020-00756-6
2. Treibel T.A., Manisty C., Burton M., McKnight Á., et al. COVID-19: PCR screening of asymptomatic health-care workers at London hospital. Lancet. 2020; 10 237 (395): 1608–10. DOI: https://doi.org/10.1016/S0140-6736(20)31100-4
3. Nguyen L.H., Drew D.A., Graham M.S., Joshi A.D., et al.; Coronavirus Pandemic Epidemiology Consortium. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Health. 2020; 9 (5): e475–83. DOI: https://doi.org/10.1016/S2468-2667(20)30164-X
4. Alserehi H.A., Alqunaibet A.M., Al-Tawfiq J.A., Alharbi N.K., et al. Seroprevalence of SARS-CoV-2 (COVID-19) among healthcare workers in Saudi Arabia: comparing case and control hospitals. Diagn Microbiol Infect Dis. 2021; 99 (3): 115273. DOI: https://doi.org/10.1016/j.diagmicrobio.2020.115273
5. Lv Z., Wang W., Qiao B., Cui X., et al. The prognostic value of general laboratory testing in patients with COVID-19. J Clin Lab Anal. 2021; 35 (2): e23668. DOI: https://doi.org/10.1002/jcla.23668
6. Xu H.M., Liu J., Gu C.G., Zhang J.D., et al. [Expressions of MPV, P-LCR and NLR in patients with novel coronavirus disease 2019]. Zhonghua Yu Fang Yi Xue Za Zhi. 2021; 55 (7): 890–5. DOI: https://doi.org/10.3760/cma.j.cn112150-20200705-00973 (in Chinese)
7. Yufei Y., Mingli L., Xuejiao L., Xuemei D., et al. Utility of the neutrophil-to-lymphocyte ratio and C-reactive protein level for coronavirus disease 2019 (COVID-19). Scand J Clin Lab Invest. 2020; 80 (7): 536–40. DOI: https://doi.org/10.1080/00365513.2020.1803587/
8. Henry B.M., de Oliveira M.H.S., Benoit S., Plebani M., Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020; 58 (7): 1021–8. DOI: https://doi.org/10.1515/cclm-2020-0369
9. Huang W., Berube J., McNamara M., Saksena S., et al. Lymphocyte subset counts in COVID-19 patients: a meta-analysis. Cytometry A. 2020; 97 (8): 772–6. DOI: https://doi.org/10.1002/cyto.a.24172
10. Diao B., Wang C., Tan Y., Chen X., et al. Reduction and functional exhaustion of t cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020; 11: 827. DOI: https://doi.org/10.3389/fimmu.2020.00827
11. Du W.N., Zhang Y., Yu Y., Zhang R.M. D-Dimer levels is associated with severe COVID-19 infections: a meta-analysis. Int J Clin Pract. 2021; 75 (8): e14031. DOI: https://doi.org/10.1111/ijcp.14031
12. Paliogiannis P., Mangoni A.A., Dettori P., Nasrallah G.K., Pintus G., Zinellu A. D-Dimer concentrations and COVID-19 severity: a systematic review and meta-analysis. Front Public Health. 2020; 8: 432. DOI: https://doi.org/10.3389/fpubh.2020.00432
13. Shah S., Shah K., Patel S.B., Patel F.S., et al. Elevated D-Dimer levels are associated with increased risk of mortality in coronavirus disease 2019: a systematic review and meta-analysis. Cardiol Rev. 2020; 28 (6): 295–302. DOI: https://doi.org/10.1097/CRD.0000000000000330
14. Ozen M., Yilmaz A., Cakmak V., Beyoglu R., et al. D-Dimer as a potential biomarker for disease severity in COVID-19. Am J Emerg Med. 2021; 40: 55–9. DOI: https://doi.org/10.1016/j.ajem.2020.12.023
15. Mojtabavi H., Saghazadeh A., Rezaei N. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis. Eur Cytokine Netw. 2020; 31 (2): 44–9. DOI: https://doi.org/10.1684/ecn.2020.0448
16. Ulhaq Z.S., Soraya G.V. Interleukin-6 as a potential biomarker of COVID-19 progression. Med Mal Infect. 2020; 50 (4): 382–3. DOI: https://doi.org/10.1016/j.medmal.2020.04.002
17. Zhao Z., Xie J., Yin M., Yang Y., et al. Interleukin-6 and severity of COVID-19 patients in Hefei, China. Med Mal Infect. 2020; 50 (7): 629–31. DOI: https://doi.org/10.1016/j.medmal.2020.06.005